Recruitment to a trial of tuberculosis preventive therapy from a voluntary HIV testing centre in Lusaka: relevance to implementation.
To determine the number of clients attending for voluntary human immunodeficiency virus (HIV) testing who are able to enter a trial of preventive therapy for tuberculosis, and the factors that determine who receives therapy, we studied 475 consecutive people attending for an HIV test at Lusaka's first voluntary HIV testing centre and the preventive therapy study clinic at the University Teaching Hospital, Lusaka, Zambia. Semi-structured interviews were conducted by counsellors and collated with recruitment data from the trial. Two hundred and twenty-five people were seropositive, of whom 201 returned to collect their results; 77 (38%) of these (16% of the total number screened) entered the trial. Reasons for not entering the trial included exclusion by trial protocol (30), including 18 who had active tuberculosis; psychological adjustment to a positive result (27); death (6); worries about confidentiality (3); the experimental nature of the trial (12); attitudes of staff in the hospital (5); and cost of transport (7). Targeting preventive therapy at those who are already choosing to be tested for HIV seems appropriate and may be cost-effective. Although visiting a hospital may deter some people, the prevalence of active tuberculosis among this group emphasized the importance of arranging adequate screening facilities.
Godfrey-Faussett
P
P
Department of Medicine, University Teaching Hospital, Lusaka, Zambia.
Baggaley
R
R
Mwinga
A
A
Hosp
M
M
Porter
J
J
Luo
N
N
Kelly
M
M
Msiska
R
R
McAdam
K
K
D015492:AIDS Serodiagnosis; D017088:AIDS-Related Opportunistic Infections / Q000150:complications*; D002986:Clinical Trials as Topic; D006801:Humans; D010342:Patient Acceptance of Health Care; D018579:Patient Selection; D012017:Referral and Consultation; D014376:Tuberculosis / Q000150:complications / Q000175:diagnosis / Q000517:prevention & control*; D015024:Zambia